Value Educator
Micro Cap Investor Looking for Under-researched and Underrated Opportunities Disc : Analysis posted here is purely for education, no recommendations are given
عرض في 𝕏سلاسل التغريدات
#LatentViewAnalytics Q3 2022 Concall Highlights Like & Retweet for better reach ! Numbers Update- 1. The revenue for Q3 was 107 cr up by 13.7% QoQ an 37.7% YoY 2. EBITDA stoo...
#ExpleoSolutions Q3 concall highlights Like & Retweet for better reach ! Numbers Update - 1. The revenue for the quarter was 120 cr up by 9% QoQ 2. EBITDA stood at Rs 187 mil...
#Deepaknitrite Q3 2022 Concall Highlights 🧪🧪 Operational Highlights 1. The revenue for the quarter was ₹1748 cr it was up 41% YoY as against ₹1240 Cr in same quarter previous y...
#DivisLaboratories Q3 FY22 concall highlights 💊💊 Like & retweet for better reach ! 1. Revenues for the quarter stood at ₹2510 Cr (46% growth YoY). 2. PBT for the quarter stood...
#StridesPharma Sciences Q3 FY22 concall highlights 💊💊 1. Revenues for the quarter stood at ₹796 Cr (5% decline YoY). 2. Gross margins decline by 840 bps YoY.
#SRF Q3 Concall Highlights 🧪🧪 Like & Retweet for better reach ! Operational Highlights 1. Revenues for the quarter stood at ₹3,345.9 as against ₹2146.4 Cr in Q3FY21, translati...
#SHKelkar Q3 2022 Concall Highlights Like & Retweet for better reach ! Operational Highlights 1. Revenues from operations stood at Rs. 396.6 crore in Q3FY22 as against Rs. 375...
#AurobindoPharma Q3 FY22 concall highlights 💊💊 Like & retweet for better reach ! 1. Revenues for the quarter stood at ₹6002 Cr (1% decline YoY).
#AlembicPharma Q3 FY22 concall highlights Like & Retweet for better reach ! 1. Revenues for the quarter stood at ₹1272 Cr (3% decline YoY). 2. EBITDA for the quarter was ₹269 C...
#Cleansciences Q3 Concall Highlights 🧪🧪 Like & Retweet for better reach Operational Highlights 1. Recorded highest ever revenue and PAT in Q3 FY2022 2. Total revenues increased...
#Piindustries Q3 Concall Highlights 🌱🧪 Like & Retweet for better reach! Operational Highlights 1. Revenues stood at ₹1356 Cr, 17% growth YoY from ₹1162 Cr in Q3FY21 2. EBITDA g...
#SupriyaLifescience Q3 FY22 concall highlights 🧪🧪 Like & Retweet for better reach ! 1. Revenues for the quarter were ₹122 Cr (43.5% growth YoY). 2. Gross profit margins have inc...